QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

VTRS

QT69Viatris Inc.
NASDAQ·Healthcare·Drug Manufacturers - Specialty & Generic·USA
Latest market price
15.37
-0.36-2.29%
OverviewShort InterestFilings
VTRSQT69Viatris Inc.·NASDAQ
OverviewShort InterestFilings
15.37-2.29%
TA
Loading chart...
Screen all →
TAK+1.36%$15.63HLN+1.01%$8.96TEVA-3.32%$31.48ELAN+3.55%$24.22RDY+1.06%$13.29RGC-18.96%$12.01LNTH+0.65%$103.86AMRX-0.43%$16.21
Snapshot
Index-P/E-EPS (ttm)
-0.26
Insider Own0.53%
Shs Outstand1.16B
Perf Week-5.76%
Market Cap18.32BForward P/E5.76EPS next Y2.67Insider Trans0.44%Shs Float-Perf Month-4.95%
Enterprise Value30.86BPEG-EPS next Q0.62Inst Own-Short Float-Perf Quarter13.85%
Income-298589455.00P/S1.26EPS this Y1049.32%Inst Trans-Short Ratio-Perf Half Y34.12%
Sales14.56BP/B1.24EPS next Y8.20%ROA-0.80%Short Interest-Perf YTD23.45%
Book/sh12.59P/C8.38EPS next 5Y-ROE-1.97%52W High17.53 -12.32%Perf Year75.46%
Cash/sh1.55P/FCF10.71EPS past 3/5Y-ROIC0.16%52W Low8.63 78.10%Perf 3Y-
Dividend Est.0.48 (3.12%)EV/EBITDA12.03Sales past 3/5Y-4.20% 3.66%Gross Margin34.40%Volatility2.69% 1.90%Perf 5Y-
Dividend TTM0.48 (3.12%)EV/Sales2.12EPS Y/Y TTM562.26%Oper. Margin0.96%ATR (14)0.50Perf 10Y-
Dividend Ex-DateMay 22, 2026Quick Ratio1.03Sales Y/Y TTM-1.19%Profit Margin-2.04%RSI (14)41.59Recom2.40
Dividend Gr. 3/5Y0.00% -Current Ratio1.60EPS Q/Q18.00%SMA20-4.24%Beta0.84Target Price17.40
Payout-188.03%Debt/Eq0.98Sales Q/Q8.08%SMA50-1.74%Rel Volume1.99Prev Close15.73
Employees32,000LT Debt/Eq0.86EarningsAug 06SMA20018.58%Avg Volume11.21MPrice15.37
IPO DateMar 17, 1980Option/ShortYes / YesEPS/Sales Surpr.17.53% 4.77%Net Debt/EBITDA4.89Volume22,261,404Change-2.29%
Analyst Ratings
DateActionAnalystRatingTarget
May-19-26ReiteratedBarclaysOverweight$15 → $22
May-08-26ReiteratedTruist Financial$18 → $20
Feb-09-26ReiteratedUBSNeutral$12 → $18
Jan-28-26ReiteratedPiper SandlerNeutral$13 → $12
Jan-16-26UpgradeArgus ResearchHold → Buy$15
Jan-07-26ReiteratedTruist Financial$15 → $16
Oct-15-25InitiatedTruistBuy$15
Jul-19-24ReiteratedJefferiesBuy$15
Mar-28-24ReiteratedPiper SandlerNeutral$10 → $13
Oct-23-23DowngradeB of A SecuritiesNeutral → Underperform
Latest News
Jun-18-26
Jun-18-2609:56PM
FDA Seeks Updated Labeling for Testosterone TherapiesYahoo
Jun-16-26
Jun-16-2601:53PM
1 Cash-Producing Stock with Exciting Potential and 2 Facing HeadwindsYahoo
10:59AM
Viatris Recognized as One of the 2026 Best Workplaces™ in CanadaYahoo
Jun-14-26
Jun-14-2608:06PM
Viatris (VTRS) Stock And The 58% Undervaluation Debate After A Strong Year Of ReturnsYahoo
06:05PM
Viatris Euro Debt Raise Reshapes Capital Structure And Valuation StoryYahoo
Jun-11-26
Jun-11-2602:05PM
Lexicon Pharmaceuticals vs. Pfizer: Which Drugmaker Stock Is a Better Buy in 2026?Yahoo
02:05PM
Lexicon Pharmaceuticals vs. Pfizer: Which Drugmaker Stock Is a Better Buy in 2026?Yahoo
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/30/2018
Total Revenue14,56314,30014,739
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A9,5539,2869,116
Gross Profit5,0105,0145,624
Selling, General and Administrative Excl. Other3,7723,7944,426
Research and Development993966809
Other Operating Expense1052,917379
Operating Income140-2,66310
Interest Expense477471550
Unusual Expense
———
Non-Operating Income (Expense)38553183
Net Income Before Taxes-815-3,665-623
Income Taxes-519-15011
Consolidated Net Income-297-3,515-634
Net Income From Continuing Operations-297-3,515-634
Net Income-297-3,515-634
EPS (Recurring)-0.26-3.00-0.53
EPS (Basic, Before Extraordinaries)-0.26-3.00-0.53
EPS (Diluted)-0.26-3.00-0.53
EBITDA2,565-3952,820
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
———
Price To Sales Ratio1.221.02—
Gross Margin34.4035.0638.16
Operating Margin0.96-18.620.07
Net Margin-2.04-24.58-4.30
Shares Outstanding1,1551,1711,193
Market Capitalization17,75214,579—
Operating Lease Expense
———
Insider Trading Volume
$17.93$16.95$15.96$14.98$14.00● Close Price0.00K70.88K141.77K212.65K283.54KUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Le Goff CorinneChief Commercial OfficerApr 15 '26Option Exercise0.0085,9760122,558Apr 16 12:00 AM
Campbell PaulSee RemarksMar 23 '26Sale13.2821,350283,539366,288Mar 24 12:00 AM
Le Goff CorinneChief Commercial OfficerMar 06 '26Option Exercise0.0092,7150101,582Mar 10 12:00 AM
Mistras TheodoraChief Financial OfficerMar 06 '26Option Exercise0.0087,564092,787Mar 10 12:00 AM
SEVERINO MICHAELDirectorMar 06 '26Option Exercise0.0052,061026,031Mar 10 12:00 AM
Enrietti AndrewSee RemarksMar 06 '26Option Exercise0.0040,2420227,477Mar 10 12:00 AM
PARRISH MARK WDirectorMar 06 '26Option Exercise0.0049,6690165,230Mar 10 12:00 AM
Campbell PaulSee RemarksMar 06 '26Option Exercise0.0057,9480398,956Mar 10 12:00 AM
MARK RICHARD ADirectorMar 06 '26Option Exercise0.0049,6690116,145Mar 10 12:00 AM
Smith Scott AndrewChief Executive OfficerMar 06 '26Option Exercise0.00261,40101,374,576Mar 10 12:00 AM
HIGGINS MELINA EDirectorMar 06 '26Option Exercise0.0049,6690146,048Mar 10 12:00 AM
Groothuis Leo FransDirectorMar 06 '26Option Exercise0.0049,669063,567Mar 10 12:00 AM
SIMMONS DAVID SDirectorMar 06 '26Option Exercise0.0046,687023,344Mar 10 12:00 AM
KILTS JAMES MDirectorMar 06 '26Option Exercise0.0049,6690161,257Mar 10 12:00 AM
Lyons Dillon JoEllenDirectorMar 06 '26Option Exercise0.0049,6690102,526Mar 10 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR